HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Raises Price Target to $24

Vanda Pharmaceuticals Inc. -1.51% Post

Vanda Pharmaceuticals Inc.

VNDA

7.16

7.16

-1.51%

-0.02% Post
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ: VNDA) with a Buy and raises the price target from $22 to $24.